Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Hamilton on Initial Findings From the LIO-1 Trial in Advanced Metastatic Tumors

October 1st 2020

Erika P. Hamilton, MD, highlights initial findings from the ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.

Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer

September 30th 2020

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Gynecologic Oncologists Continue to Pursue Novel Agents, Immunotherapy in Ovarian Cancer

September 30th 2020

Caroline Billingsley, MD, spoke to established and emerging treatment modalities in ovarian cancer and the successes and pitfalls of key clinical trials of antibody-drug conjugates and immunotherapy in this space.

Maintenance PARP Yields Impressive PFS Benefit in Recurrent, Platinum-Sensitive Ovarian Cancer

September 30th 2020

Amanda L. Jackson, MD, , discusses the role of PARP inhibitors in the maintenance treatment of patients with recurrent platinum-sensitive ovarian cancer.

Pivotal Trials Cast PARP Inhibitors into Frontline Maintenance Therapy in Ovarian Cancer

September 30th 2020

Thomas Herzog, MD, discusses the data that have cast PARP inhibitors into the forefront of treatment in the up-front management of patients with advanced ovarian cancer.

Secondary Cytoreduction Plays Role in Recurrent Ovarian Cancer Management, But Selection Is Key

September 29th 2020

Michael Guy, MD, discusses pivotal trials that have helped to define the role of secondary cytoreductive surgery in recurrent ovarian cancer.

Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer

September 21st 2020

The addition of atezolizumab to a backbone comprised of bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.

Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer

September 21st 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.

Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer

September 21st 2020

Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.

EMA Recommends Approval of Olaparib/Bevacizumab for Frontline Maintenance in HRD+ Advanced Ovarian Cancer

September 21st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for olaparib as maintenance treatment in adult patients with advanced, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response after first-line platinum-based chemotherapy plus bevacizumab and whose disease has homologous recombination deficiency positivity defined by either a BRCA1/2 mutation and/or genomic instability.

QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial

September 20th 2020

Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.

Dostarlimab Demonstrates Durable Antitumor Activity in Mismatch Repair Proficient/dMMR Endometrial Cancer

September 20th 2020

Dostarlimab showcased durable antitumor activity in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer, with a notable disease control rate and a promising safety profile.

Balstilimab Monotherapy or Plus Zalifrelimab Active in Recurrent/Metastatic Cervical Cancer

September 19th 2020

The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer.

Niraparib Granted Positive EU Opinion for Frontline Maintenance in Advanced Ovarian Cancer

September 18th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for niraparib for frontline maintenance treatment in patients with advanced ovarian cancer who are responsive to platinum-based chemotherapy.

FDA Approves Expanded Use of CINtec PLUS Cytology Test to Prevent Cervical Cancer in HPV+ Women

September 16th 2020

The FDA has approved the expanded use of the CINtec PLUS Cytology assay for women who undergo cervical cancer screening and test positive for high-risk types of human papillomavirus.

Lucitanib/Nivolumab Combo Enters Phase 2 Evaluation for Gynecologic Cancers

September 11th 2020

The first patient has been enrolled on the phase 2 portion of the LIO-1 trial, which will examine the combination of lucitanib plus nivolumab in those with gynecologic cancers.

STRO-002 Shows Early Efficacy, Safety in Heavily Pretreated Epithelial Ovarian Cancer

September 11th 2020

The novel anti-folate receptor alpha antibody-drug conjugate STRO-002 demonstrated encouraging efficacy with a tolerable safety profile in patients with advanced platinum-resistant or refractory epithelial ovarian cancer.

Niraparib Approved in China for Frontline Maintenance in Ovarian Cancer

September 10th 2020

The China National Medical Products Administration has approved niraparib for use as a first-line maintenance treatment in adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieve a complete or partial response to first-line platinum-based chemotherapy.

Dr. Westin on Remaining Challenges in Endometrial Cancer

September 10th 2020

Shannon N. Westin, MD, MPH, discusses remaining challenges in endometrial cancer.

Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer

September 7th 2020

In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.